BIVI Places Voluntary Stop Sale on Pigeon Fever Condionally Licensed Vaccine - Business Solutions for Equine Practitioners | EquiManagement

BIVI Places Voluntary Stop Sale on Pigeon Fever Condionally Licensed Vaccine

Author:
Publish date:

Editor's Note: Boehringer Ingelheim Vetmedica Inc. sent the following information to individual veterinarians and distributors, and we wanted to ensure that everyone had the updated information from BIVI.

As of April 9, 2015, Boehringer Ingelheim Vetmedica, Inc. (BIVI) has placed a voluntary stop sale on its U.S. conditionally licensed Corynbebacterium Pseudotuberculosis Bacterin-Toxoid vaccine, more commonly known as the Pigeon Fever vaccine. The voluntary stop sale is due to reports of unexpected post-vaccination gastrointestinal tract events observed in some horses. During the required pre-licensing safety studies, these events were not observed.

We are committed to supplying the highest quality products to our customers, and believe a voluntary stop sale is in the best interest of our customers and their horses.

A comprehensive investigation is underway to understand the unexpected post-vaccination events observed in some horses, as these events were not observed during the pre-licensing safety studies.

Medical and technical questions should be directed to the BIVI Veterinary Technical Services Team at 1-866-638-2226 (Monday through Friday 8 a.m.-5 p.m. CST).

We are fully committed to providing veterinarians and horse owners with the highest quality products for horse health, and to researching and developing products that will offer horses protection from current and future diseases and conditions.